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Abstract
Background: The determination of altered expression of genes in specific tumor types and their effect upon cellular
processes may create insight in tumorigenesis and help to design better treatments. The Flatcoated retriever is a dog breed
with an exceptionally high incidence of histiocytic sarcomas. The breed develops two distinct entities of histiocytic
neoplasia, a soft tissue form and a visceral form. Gene expression studies of these tumors have value for comparable human
diseases such as histiocytic/dendritic cell sarcoma for which knowledge is difficult to accrue due to their rare occurrence. In
addition, such studies may help in the search for genetic aberrations underlying the genetic predisposition in this dog
breed.
Methods: Microarray analysis and pathway analyses were performed on fresh-frozen tissues obtained from Flatcoated
retrievers with localized, soft tissue histiocytic sarcomas (STHS) and disseminated, visceral histiocytic sarcomas (VHS) and on
normal canine spleens from various breeds. Expression differences of nine genes were validated with quantitative real-time
PCR (qPCR) analyses.
Results: QPCR analyses identified the significantly altered expression of nine genes; PPBP, SpiC, VCAM1, ENPEP, ITGAD
(down-regulated), and GTSF1, Col3a1, CD90 and LUM (up-regulated) in the comparison of both the soft tissue and the
visceral form with healthy spleen. DAVID pathway analyses revealed 24 pathways that were significantly involved in the
development of HS in general, most of which were involved in the DNA repair and replication process.
Conclusions: This study identified altered expression of nine genes not yet implicated in histiocytic sarcoma manifestations
in the dog nor in comparable human histiocytic/dendritic sarcomas. Exploration of the downside effect of canine inbreeding
strategies for the study of similar sarcomas in humans might also lead to the identification of genes related to these rare
malignancies in the human.
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Introduction
Fundamental research on rare human diseases is not only
hampered by minimal grant supply; lack of sufficient sample
numbers is of equal disadvantage. One way to overcome this last
catch, is to investigate other species in which a similar disease
occurs at a much higher frequency, like in specific dog breeds. In
dogs, a downside of selection for breeding purposes is the
occurrence of a very large number of breed-specific hereditary
diseases (http://omia.angis.org.au/home/). Rare human diseases,
such as histiocytic malignancies, might therefore be common in
specific dog breeds [1].
The Flatcoated retriever (FCR) breed has a strongly increased
risk for histiocytic sarcoma (HS) development. In the UK, it is
likely to account for about 36% of all malignant neoplasms
diagnosed in this breed [2,3].
Canine histiocytic malignant disorders were as such first
described in the late 1970s [4]. Included in the name ‘histiocytic
sarcoma’, which was given to the complex of malignant histiocytic
disorders [5], there is a range of malignant tumors derived from
CD34-committed stem cell precursors that may develop into
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e71094
dendritic cells (DC) such as Langerhans cells, interstitial DC and
macrophages [6,7]. In addition to morphological features, most
histiocytic sarcomas can be recognized by positive immunostaining
for the cell surface marker CD18 [6–8]. Canine HS has
resemblance to the rare and often lethal human histiocytic
malignancies, including dendritic cell and histiocytic sarcomas
and disseminated Langerhans cell histiocytosis (LCH) [9–12].
Histiocytic sarcomas in dogs almost inevitably metastasize to
various organs [10] and have a very poor prognosis [2,10,11]. A
median survival of four months has been reported in the FCR [3].
In dogs, there are several clinical manifestations of HS. One
common form is the localized, soft tissue histiocytic sarcoma
(STHS), which manifests itself as a tumor arising in the deeply
seated soft tissues of limbs often in association with joints
[2,3,10,13]. A second common form is manifested in internal
organs and often multifocal and named disseminated, visceral
histiocytic sarcoma (VHS), with neoplastic changes that can be
found in either spleen, liver, lung and/or bone marrow [6].
Past research using Comparative Genomic Hybridization has
already shown various aberrations in HS in the Bernese Mountain
Dog, another breed predisposed to histiocytic malignancies, with
cases showing numerous shared Copy Number Alterations (CNAs)
both gains and losses, throughout the genome. These included
deletions of the tumor suppressor genes CDKN2A/B, RB1 and
PTEN [10]. Furthermore, an associated constitutional haplotype in
a locus near to the highly cited tumor suppressor locus MTAP-
CDKN2A has recently been identified in this breed [1]. Another
study concluded that deregulation of the expression of the
glycation end products (Receptor for Advanced Glycation End-
products; RAGE) and the high mobility group box1 protein
(HMGB1) potentially have a major effect on the progression of
malignant histiocytic disorders [14].
cDNA microarrays have become powerful tools in the study of
gene expression which has enabled improved classification of
various naturally occurring cancers [15,16] and have, once the
canine genome sequence became available [17] already proven
their value in the research of various canine sarcomas [18–20] but
not yet in HS. Thus, we examined shared genetic functional
aberrations of HS by comparing both forms of HS with normal
tissue, for which spleen was chosen.
The study of spontaneously occurring tumors in the dog, a
species which has a genetically stronger relationship to the human
than mice [21,22] can enrich the knowledge of rare human
cancers, and lead to more insight in the pathogenesis of the disease
and facilitate the identification of therapeutic targets valuable for
dog and human [1,11,18,20,21]. The outcome of this study
provides evidence of the existence of common differences in gene
activity between HS and normal spleen.
Materials and Methods
The experimental protocol (ID 2007.III.08.110) was peer-
reviewed by the scientific committee of the Department of Animals
in Science & Society, Utrecht University, The Netherlands, and
approved by the Animal Experiments Committee of the Academic
Biomedical Centre, Utrecht, The Netherlands. The Animal
Experiments Committee based its decision on ’De Wet op de
Dierproeven’ (The Dutch ’Experiments on Animals Act’, 1996)
and on the ’Dierproevenbesluit’ (the Dutch ’animal experiments
decree’, 1996). Both documents are available online at http://
wetten.overheid.nl.
Case Recruitment and Histopathological Evaluation
All tumor samples were confirmed as being spontaneously
occurring histiocytic malignancies and were obtained from family-
owned FCR with informed owner consent. All tumor material
used originated from the Dutch FCR, that had not received
radiotherapeutical or cytostatic treatment. Tumors were obtained
under sterile conditions, either as part of a routine diagnostic or
therapeutic surgical procedure, or immediately following eutha-
nasia. Directly after excision, samples were snap frozen in liquid
nitrogen, or alternatively by primary preservation in RNA-later, in
both instances followed by storage at minus 70uC. Tumor samples
collected adjacent to the site of the frozen or RNA-later preserved
samples were fixed in 10% neutral buffered formalin and routinely
processed for histological examination.
At the time of surgery or necropsy, the evident anatomical
location of all tumors was recorded for each individual and
categorized as either VHS, if a tumor was present in internal
organs (n = 7) or STHS, if the tumor was localized in a limb only
without identifiable metastases (n = 6) [8].
Histological specimens were classified by a board-certified
veterinary pathologist (GCMG) according to the recommenda-
tions and classification scheme defined by Affolter and Moore [6].
In all cases immunohistochemical staining with antibodies against
CD18 protein (the common subset of b2 adhesion integrins,
expressed in histiocytes, dendritic cells (DC), lymphocytes, and
polymorphonuclear leukocytes [23]) were used to confirm the
suspected histiocytic origin [8]. Results of this staining were
divided in two categories: negative or positive. If the differential
diagnosis based upon morphology included the potential origin of
other malignant round cell tumors (malignant lymphoma,
mastocytoma, melanoma, myeloma) appropriate immunostaining
to examine such potential histogentic origin was performed and
had to be negative. All tumor samples selected for the genetic
study contained over 50% tumor cells as assessed in histological
sections of biopsies of adjacent tissue. Patient details are listed in
Table 1.
As control tissue, normal spleen from (healthy) crossbreed dogs
(n = 6) was used as obtained at postmortem immediately following
euthanasia that was not related to neoplastic, endocrine or
metabolic diseases.
As a common reference pool a multitude of canine organs
(testis, liver, spleen, prostate, duodenum, lung, kidney and brain)
were used that had been obtained from healthy crossbreeds (n = 8)
euthanized for non-metabolic, non-tumorous lethal conditions.
The procedures were approved by the local ethics committee, as
required under Dutch legislation (ID 2007.III.08.110).
RNA Isolation
Approximately 30 mg of frozen tumor was transferred to a
container with 600 ml of Buffer RLT and was disrupted/lysed and
homogenized using a dismembrator (Braun Biotech Int., Melsun-
gen, Germany) for 45 s at 2200 rpm. Total RNA was isolated and
treated with DNase using the RNeasy mini kit (Qiagen, The
Netherlands) according to the manufacturer’s protocol. Quantity
and integrity were assessed with the Bioanalyzer Agilent
BioAnalyzer-2100 (Bioanalyzer, Agilent Technologies, Santa
Clara, CA) in combination with an RNA 6000 Pico-LabChip.
The average RNA integrity number 8.5 (range: 7.2–9.8) was found
to be appropriate [24]. RNA concentration was quantified using a
NanoDrop ND-1000 (Isogen Life Science) spectrophotometer.
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Expression Profiling
RNA was labeled twice and hybridized against the common
reference RNA on dual channel arrays. RNA concentrations were
0.6 mg/ml at a minimum amount of 3 mg per sample.
RNA amplifications and labeling were performed on an
automated system (Caliper Life Sciences NV/SA, Belgium) as
described [25]. Dye swap of Cy3 and Cy5 was performed to
reduce dye bias. Hybridizations were done on a HS4800PRO
system supplemented with QuadChambers (Tecan Benelux
B.V.B.A.) using 500–1000 ng labeled cRNA per channel as
described [26]. Microarrays used were Agilent Canine Gene
Expression Microarrays V1 (Agilent Technologies, Belgium)
representing 42,035 canine 60-mer probes in a 4644 K layout.
Hybridized slides were scanned on an Agilent scanner
(G2565BA) at 100% laser power, 30% photomultiplier tube
voltage. After automated data extraction using Imagene 8.0
(BioDiscovery), printtip Loess normalization was performed [27]
on mean spot-intensities. Dye-bias was corrected based on a
within-set estimate as described [28].
Analyses were performed to detect common differences in gene
expression between the two groups of HS and healthy spleen
tissue. Data were analyzed using ANOVA [29] (R version 2.2.1/
MAANOVA version 0.98–7) (http://www.r-project.org/). In a
fixed effect analysis, sample, array and dye effects were modeled.
P-values were determined by a permutation F2-test, in which
residuals were permutated 5,000 times globally. Genes with
P,0.0002 after either family wise error correction (FWER) or
determination of false discovery rate (FDR) were considered
significantly changed. Genes with log2-fold changes of more than
0.5 or less than 20.5 were then selected to ensure that only robust
changes were considered.
The Gene Ontology (GO) database (http://www.geneontology.
org/) was used to check gene molecular and biological functions of
the remaining genes.
Functional Annotation
In general, pathway analysis in dogs has its restraints because
pathway identification relies heavily on existing functional
annotation, which is still limited for this species. Still, pathway
analysis provides an additional way to analyze expression data
across species. This may shed light on common pathways
important for tumor behavior and on finding new therapeutic
targets. To examine whether certain pathways are over- or under-
represented in the gene list, all genes significantly differentially
expressed between either STHS, VHS and normal spleen, were
introduced into DAVID (http://david.abcc.ncifcrf.gov/).
Quantitative Real Time PCR
Gene selection. Following the outcome of the microarray
expression profiling, ten genes were selected. Selection of ten genes
was based on significantly differently expression, M-fold changes
and potential biological function in relation with tumor develop-
ment.
These genes including their optimum temperature are listed in
Table 2.
RNA Isolation and cDNA Synthesis
Tissues from all but one patient (of which the insufficient tissue
remained for the qPCR experiment) were used in the microarray
experiment (six spleens, six STHS and seven VHS), furthermore
three additional samples (one normal spleen, one STHS and one
VHS that met the inclusion criteria) were added thus creating 3
groups of seven samples for the qPCR experiment. Total RNA
from these samples was isolated. After isolation, total RNA was
treated with DNase using the RNeasy mini kit (Qiagen, The
Netherlands) according to the manufacturer’s protocol.
Reverse transcription (RT) was performed of all 20 samples in a
80 ml reaction using 2000 ng total RNA, 16 ml iScript Reaction
mix and 4 ml iScript Reverse Transcriptase (iScript cDNA
Synthesis kit, Bio Rad, Veenendaal, The Netherlands). This
includes a mixture of oligo-dT random hexamer primers. The
mixture was incubated 5 min. at 25uC, 30 min. at 42uC and
followed by 5 min. at 85uC. Minus RT controls were prepared
from 500 ng of the same RNA under the same conditions, but
without addition of reverse transcriptase.
Reference Genes and Primer Development
Reference genes were selected as non-regulated reference genes
for normalization based on their stable expression in canine tissue
[30,31].
Using Ensembl, through annotated transcripts, PCR primers
were designed using the Perl Primer software (version 2.0.0.7) and
primer3 software (version 0.4.0) according to the parameters
outlined in the Bio-Rad i-cycler manual. The specificity of each
primer pair was confirmed by sequencing its product and also in
qPCR by checking the meltcurve and reaction efficiency.
GeneNorm was used to establish expression stability [32].
Amplicon sequence-reactions were performed using BigDye v3.1
according to the manufacturer’s (Life Technologies, Bleiswijk, The
Netherlands) instructions on an ABI31306L and analyzed in
Lasergene (version 9.1 DNASTAR) and confirmed the specificity
of each amplicon. Using RefFinder, the stability of nine reference
genes were checked. In Figure 1 they are listed according to their
stability. Four of the more stable primers were chosen for further
Table 1. Patient details.
Name Sex Pathology
AO
(yrs) Site(s)
Microarray/
PCR
D1, TJ MN STHS 7.7 shoulder Y/Y
D3, UH FN STHS 8 shoulder Y/Y
D4, BS MN STHS 6.5 elbow Y/Y
D5, BaS M STHS 7.6 knee Y/Y
D6, TV MN STHS 8.1 elbow Y/Y
D7, DV MN STHS 11 shoulder Y/Y
DX, YM MN STHS 9.7 shoulder N/Y
D2, BE M VHS 9.4 liver/spleen/
lnn abd
Y/Y
D8, DW M VHS 9.5 spleen/lnn abd Y/N
D9, JV FN VHS 8.9 lung/lnn mediast Y/Y
D11, BT F VHS 8.5 lung Y/Y
D12, AG M VHS 7.3 lung/spleen/
kidney
Y/Y
D13, TR FN VHS 7.9 lung Y/Y
D14, SG F VHS 4.1 lung/lnn mediast Y/Y
DX, SC MG VHS 10 liver/spleen N/Y
AO: Age of onset, M: male, MN: male neutered, F: female, FN: female neutered,
STHS: soft tissue (localized) histiocytic sarcoma, VHS: visceral (disseminated)
histiocytic sarcoma, lnn abd: abdominal lymphnodes, lnn mediast: mediastinal
lymph nodes Note: For cases with VHS the site sampled for gene expressionis
indicated in bold letters.
doi:10.1371/journal.pone.0071094.t001
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data analysis, namely ribosomal protein S5 (RPS5), signal recognition
particle receptor (SRPR), ribosomal protein L13(RPL13), hypoxanthine
phosphoribosyltransferase (HPRT).
Primers for all nine reference genes, including their optimum
temperature are listed in Table 3.
Quantative PCR
For qPCR, the Bio-Rad detection system (Bio-Rad.) with SYBR
green fluorophore was used. Reactions were performed in a total
volume of 25 ml containing 12.5 ml of 26SYBR green super mixes
(Bio-Rad Laboratories Ltd.), 1 ml of each primer at 400 nM
concentration, 0.8 ml of cDNA and 9.7 ml Rnase and Dnase free
water as previously described [33,34]. Q-PCR reactions for each
primer set were optimized by performing reactions under a
gradient of annealing temperature using three serial 166dilutions
of pooled cDNA from all tissue samples. Cycling conditions were
as follows: Denaturation (95uC for 5 min.), amplification cycle
repeated 45 times (95uC for 10 sec, 30 sec at the primer specific
annealing temperature (Table 2) and 30 sec at 72uC. The last step,
30 sec at 72uC was omitted when the annealing temperature was
higher than 58uC. A melting curve analysis was performed
following every run to ensure a single amplified product for every
reaction. All reactions were performed in duplicate. The reference
standard dilution series was repeated on every plate. Duplicate
negative controls, both a minus RT and a water control, were run
with every experimental plate to assess the specificity and to
identify any potential contamination.
Table 2. QPCR primers for genes of interest based on Microarray and pathway analyses.
Gene name Accession number Primer sequence (5’–3’) Forward/reverse
Annealing
T(6C)
Size
(bp)
PPBP XM_539315 ACTGTCTCTGGCATTCATCC F 59 116
AGGCAGATTCTCTTCCCATT R
GTSF1 XM_534784.3 GCAGAAAGAATCATCCTGATGTC F 57 221
GATCTTTATCCCAGTCTTCATCG R
Spi-C XM_849901.2 AATTACCTGGCTTTCATCAACC F 57 114
CAGCACTGTTTATTACTGTTCTCC R
VCAM1 NM_001003298 CTACAAGTCTACATCTCACCCA F 58 213
TTCCAGAATCTTCCAGCCTC R
ENPEP XM_535696.3 GCTTCCTTCTTTGAGTTCCT F 58 266
TTCCAAGTAAATCTGGCATCCT R
LUM XM_539716.3 CAAGACAGAAGGATTCAAAGCA F 55 132
GATGACAGCCCATAAATCGG R
ITGAD XM_843683.2 TCTTGTATTGAACTGCTCCA F 57 261
GTTGTAGACCTCATACTTCTCC R
Col3A1 XM_845916 ATAGAGGCTTTGATGGACGAA F 65 132
CCTCGCTCACCAGGAGC R
MYH11 XM_857838 GAGAGGACCAGTCCATTCTG F 59 253
GATGAATTTGCCAAATCGTGAG R
Thy1 XM_844606.2 CTGTGCTCAGAGACAAACTG F 58 185
TTAGCCAACTCAGAGAAAGTAGG R
Common genes chosen for qPCR development identified using microarray as being significantly different in both disseminated, Visceral Histiocytic Sarcoma (VHS) and
localized, Soft Tissue Histiocytic Sarcoma (STHS) compared to spleen. PPBP: Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7), GTSF1: Gametocyte specific factor 1,
SPIC: Spi-C transcription factor, VCAM1: Vascular cell adhesion molecule 1, ENPEP: Glutamyl aminopeptidase (aminopeptidase A), LUM: Lumican, ITGAD: Integrin, alpha D,
Col3A1: Collagen, type III, alpha 1, MYH11: Myosin, heavy chain 11, smooth muscle, Thy-1 (CD90): Thy-1 cell surface antigen.
doi:10.1371/journal.pone.0071094.t002
Figure 1. Gene stability by Genorm for all nine reference genes.
Horizontal axis: Least stable genes (left) and most stable genes (right)
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), b-2-Microglobu-
lin (B2MG), Ribosomal protein S5 (RPS5), Ribosomal protein S19 (RPS19),
Hypoxanthine phosphoribosyltransferase (HPRT), Ribosomalprotein L8
(RPL8), B-Glucuronidase (GUSB), Signal recognition particle receptor
(SRPR), and Ribosomal protein L13 (RPL13).
doi:10.1371/journal.pone.0071094.g001
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Data analysis was performed with IQ5 Real-Time PCR
detection system software (BioRad). Expression levels were
normalized using the average relative amount of the reference
genes. Log-values of normalized relative expression were used to
obtain normal distribution.
A Wilcoxon rank sum test was performed to determine the
significance of differential gene expression. All results were
Bonferroni corrected.
Results and Discussion
Differentiation between STHS and VHS was based on physical
examination and radiographic (thorax)/ultrasound examination
(thorax/abdomen). All dogs with visceral organ involvement were
euthanized followed by immediate autopsy. Histomorphology and
immunohistochemical staining for CD18 confirmed the suspected
histiocytic origin of tumors studied.
The Microarray enabled analysis of the expression of 42,034
features. Since only 21,682 (51% ) were annotated (CanFam 2.0),
it is possible that important genes are missed. When comparing
VHS and spleen, 4,235 features were significantly differentially
expressed. When only looking at 4-foldchanges or larger, 352
features remained. When comparing STHS with spleen, 5,779
features were significantly differentially expressed. In this com-
parison, when only looking at 4-foldchanges or larger, 437 features
remain.
Of the total of altered genes, 3,394 features were significantly
differentially expressed in both forms of HS versus normal spleen,
and 319 features remained when only 4-foldchanges or larger are
taking into account.
Figure 2 visualizes the heatmap of the ten genes that were
chosen for qPCR confirmation.
In order to improve knowledge on the genetic basis of HS and
to best exploit logistic and financial resources, we chose to examine
a selection of the significantly altered genes found in the
microarray experiment for confirmation by qPCR. Selection of
genes was based on the statistical significance of their differential
expression and their potential involvement in tumor development.
Since it is not possible to obtain pure samples of sedentary, non-
tumorous histiocytes for expression profiling, spleen tissue was
chosen as the normal equivalent of HS. HS arises from interstitial
DC, and hence emanate from lymphoid domains when these arise
from lymphoid organs such as the spleen [6], choosing spleen as a
control tissue is a logical choice.
As a result from the qPCR experiment, significantly altered
expression was confirmed for nine of the ten genes analyzed.
PPBP, SpiC, VCAM1, ENPEP and ITGAD were downregulated and
GTSF1, LUM, Thy1 and Col3a1 were upregulated in both STHS
and VHS compared to normal spleen. Table 4 shows the adjusted
p-values and Fold Change.
The use of spleen as the healthy equivalent of HS does raise
some concern as to how observed differences in Spi-C and VCAM1
gene expression between tumors and healthy spleen must be
explained. It is possible that some of these expression differences
are based on differences in tissue-origin rather than on actual
tumor development. Spi-C plays a critical role in the development
of splenic iron homeostasis. It is highly expressed in red pulp
macrophages, but not monocytes, dendritic cells or other tissue
macrophages. Spi-C is therefore highly expressed in spleen [35],
and could thus lead to cause a seemingly relative down-regulation
in HS tissues. Spi-C is also known to regulate VCAM1 expression
[35]. This gene is thought to be involved in angiogenesis and is
induced by cytokines on endothelial cells [36]. Since spleen tissue
contains abundant endothelium, this could cause the relative high
expression of VCAM1 in the spleen. ITGAD (also known as CD11d)
Table 3. Reference genes primers for qPCR.
Gene name Accession number Primer sequence Forward/ Reverse
Annealing
T(6C) Size (bp)
HPRT AY283372 AGCTTGCTGGTGAAAAGGAC F 56 104
TTATAGTCAAGGGCATATCC R
RPS19 XM_533657 CCTTCCTCAAAAAGTCTGGG F 61 95
GTTCTCATCGTAGGGAGCAAG R
RPL8 XM_532360 CCATGAATCCTGTGGAGC F 55 64
GTAGAGGGTTTGCCGATG R
SRPR XM_546411 GCTTCAGGATCTGGACTGC F 61 81
GTTCCCTTGGTAGCACTGG R
RPL13 AJ388525 GCCGGAAGGTTGTAGTCGT F 61 87
GGAGGAAGGCCAGGTAATTC R
GUSB NM_001003191 AGACGCTTCCAAGTACCCC F 62 103
AGGTGTGGTGTAGAGGAGCAC R
GAPDH NM_001003142 TGTCCCCACCCCCAATGTATC F 58 100
CTCCGATGCCTGCTTCACTACCTT R
B2MG XM_535458 TCCTCATCCTCCTCGCT F 61 85
TTCTCTGCTGGGTGTCG R
RPS5 XM_533568 TCACTGGTGAGAACCCCCT F 62.5 141
CCTGATTCACACGGCGTAG R
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), b-2-Microglobulin (B2MG), Ribosomal protein S5 (RPS5), Ribosomal protein S19 (RPS19), Hypoxanthine
phosphoribosyltransferase (HPRT), Ribosomalprotein L8 (RPL8), B-Glucuronidase (GUSB), Signal recognition particle receptor (SRPR), and Ribosomal protein L13 (RPL13).
doi:10.1371/journal.pone.0071094.t003
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is a receptor for VCAM1. In our study, we detected a lowered
expression of CD11d in HS as compared to normal spleen.
Staining by immunohistochemistry for the presence of CD11d
in both STHS and VHS was found negative in a first study by
Moore et al, including16 splenic HS [6] and this absence of the
CD11d protein in HS was seen as one of the phenotypically
characteristics of a myeloid dendritic antigen-presenting cell
lineage, making many HS to be likely myeloid dendritic cell
sarcomas [6]. In contrast, a more recent study in Flatcoated
Retrievers found the majority (12/20) of splenic HS positive for
CD11d [8] and was interpreted by the investigators as marker of a
likely red-pulp macrophagocytic origin of these splenic HS. A
similar rate of CD11d positivity was noticed by another study by
Moore et al examining hemophagocytic HS in spleen in a series of
dogs from 6 breeds [7]. CD11d proteins appear to be strongly
expressed only on mature granulocytes, monocytes, and certain
lymphocytes, but not significantly on myeloid committed precur-
sor cells [37] and hence, the low expression in many HS is no
surprise as is its positivity in hemophagocytic HS. Still, the finding
of positive expression in splenic HS by immunohistochemistry [8]
is at variance with earlier studies [6] and was interpreted as marker
of a likely red-pulp macrophagocytic origin of these splenic HS. In
our study, we detected a lowered expression of CD11d in HS as
compared to normal spleen.
The down-regulation of PPBP as was found in this study, has
also been reported to play a role in the development of myelomas
[38] as well as pancreatic cancers [39], in the latter report the
PPBP (CXCL7) plasma-level was even postulated to be an
interesting biomarker for early detection [39]. The close relation
in the origin of myeloma and histiocytic sarcoma, both stemming
Figure 2. Microarray-based heatmap of the ten genes chosen for qPCR. PPBP: Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7),
GTSF1: Gametocyte specific factor 1, SPIC: Spi-C transcription factor, VCAM1: Vascular cell adhesion molecule 1, ENPEP: Glutamyl aminopeptidase
(aminopeptidase A), LUM: Lumican, ITGAD: Integrin, alpha D, Col3A1: Collagen, type III, alpha 1, MYH11: Myosin, heavy chain 11, smooth muscle, Thy-
1 (CD90): Thy-1 cell surface antigen.
doi:10.1371/journal.pone.0071094.g002
Table 4. Genes identified as potential interesting using gene profiling in both VHS and STHS compared to spleen.
Gene name
qPCR:Adj p-values VHS vs
Spleen
qPCR:Adj p-values STHS vs
Spleen
qPCR:Up/Down regulated
versus spleen
Spleen versus VHS resp STHS;
Fold Change
PPBP 7.661028 7.2361029 DOWN 23606, 210086
GTSF1 2.961024 5.2561025 UP 10006, 10006
Spi-C 2.061023 2.461024 DOWN 2126, 2516
VCAM1 0.011478 1.1 1024 DOWN 2106, 266
ENPEP 8.461024 2.061028 DOWN 23246, 214726
LUM 3.461023 5.4361027 UP 886, 486
ITGAD(CD11d) 8.561023 1.661023 DOWN 246, 22536
Col3a1 7.061023 0.010 UP 236, 186
Thy1 (CD90) 0.024 4.19E-05 UP 36, 66
PPBP: Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7), GTSF1: Gametocyte specific factor 1, SPI-C: Spi-C transcription factor, VCAM1: Vascular cell adhesion
molecule 1, ENPEP: Glutamyl aminopeptidase (aminopeptidase A), LUM: Lumican, ITGAD: Integrin, alpha D, Col3A1: Collagen, type III, alpha 1, Thy-1 (CD90): Thy-1 cell surface
antigen.
doi:10.1371/journal.pone.0071094.t004
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from lineages of hematoproliferative compartments makes this
downregulation of PPBP an intriguing observation worthy of
further pursuit.
Expression and overexpression of LUM has been observed in
various types of cancer cells (colorectal, pancreatic, and breast
cancer, melanoma, neuroendocrine cell tumors) - with contrasting
findings on the relation with type of growth and/or tumor
progression or metastasis [40–46] - and in activated synoviocytes
from rheumatoid arthritis [47]. The function of lumican - a
member of the family of small leucine rich proteoglycans - in the
organization of the extracellular matrix composition as well as in
migration and proliferation- in relation to the observed overex-
pression in HS warrants further investigations, including the site of
overexpression (tumor cell or tumor-associated fibroblasts) [48].
In humans, an up regulation of GTSF1 is already known in the
occurrence of mycosis fungoides, which is the most common type
of primary cutaneous T-cell lymphoma, in which GTSF1 was
proposed as a gene for which expression appears to be restricted to
mycosis fungoides tumor stage and that might even serve as
diagnostic (bio)marker [49].
ENPEP probably plays a role in regulating growth and
differentiation of early B-lineage cells (http://www.wikigenes.
org/e/gene/e/13809.html) and down regulation may thus also be
involved in HS development.
Finally, Col3a1 also has been shown to be overexpressed in other
types of tumors, such as malignant mesothelioma [50], as well as in
human sarcoma xenotransplants [51]. Its overexpression could
have a significant influence upon extracellular matrix composition
[52].
Thy1 (CD90) is an important marker of many types of stem cells
[53], including mesenchymal stem cells [54]. CD90 has already
been identified as a candidate marker for cancer stem cells in
primary high-grade gliomas using tissue microarrays [55,56]. For
human hepatocellular carcinoma, CD90 has even been shown to
provide a clinical prognostic marker [53]. Our observation of
overexpression of CD90 in HS might herald stem cell character-
istics of the type of cancer.
For technical reasons, no qPCR data could be obtained for
Myh11.
As a result of the pathway analyses in DAVID, 24 pathways
were significantly involved in the development of HS (P,0.05).
Most were involved in the DNA repair and replication process.
The biological functions of ten of these pathways, amongst which
the P53 signaling pathway was one of the most relevant, are listed
in Table 5.
Our observations provide evidence of an association between
altered expression of nine genes (PPBP, SpiC, VCAM1, ENPEP,
ITGAD, GTSF1, COL3A1, CD90 and LUM) and development of
HS in the Flatcoated retriever dog, irrespective of the disseminated
or localized form.
Based upon a fundamental and evolutionarily conserved
association between cytogenetic abnormalities and tumor
phenotype in different species [10,57] these genes may be of
major interest in the study of histiocytic malignancies in the
human as well. There exists a great difference in incidence of
histiocytic malignancies between this specific dog breed as
compared to the human. This implies a genetic make-up
predisposing the Flatcoated retriever (and the Bernese Mountain
Dog); which is uncommon in many other dog breeds and
humans alike. For the Bernese Mountain Dog, a first genetic
locus has been identified. Our group takes part in a study
aiming to identify predisposing genes in the Flat Coated
Retriever in the hope, that these findings may provide clues
for the related cancer in the human.
The current study provides the most comprehensive database
of genome alterations in histiocytic malignancies to date,
revealing genes and signaling pathways not previously associated
with this disease. Although mRNA levels do not necessary
reflect differences in protein levels, it is very well conceivable
that the large difference in mRNA levels of specific genes will
result in quantitative differences in protein expression. Lack of
verified and specific antibodies for all nine gene products of
interest let us to restrain this expression profiles to mRNA levels
only. The study of Hedan [10] was able to locate recurrent
genomic imbalances using CGH. As indicated in Table 3 of
their publication [10], 808 genes found to be located in their
regions of interest. This covers about 4% of the total number of
genes. In the Agilent Canine Gene Expression Microarrays V1
that were used in our study, 430 of these 808 genes were
annotated. Three of these annotated genes; EN-
SCAFG00000007012 (SPIC), ENSCAFG00000001046 (DESI1)
and ENSCAFG00000006138 (LUM) were found to be com-
monly involved in our study as well as in Hedans study. In our
study, eventually two of these genes, SPIC and LUM, were
chosen for qPCR confirmation. We were indeed able to identify
the significantly altered expression of these two genes.
Conclusion
This is the first study to compare gene expression in HS (both
STHS and VHS) and normal spleen using both traditional fold
change analysis as well as disease-based pathway analyses using
DAVID.
This study provides evidence for involvement of several genes in
HS, irrespective of the form of manifestation, some of which are
also related with to other cancers. On the basis of quantitative
differences in expression, we consider PPBP, SpiC, VCAM1,
ENPEP, ITGAD (down-regulated), and GTSF1, Col3a1, CD90 and
LUM (up-regulated) to be associated with the HS genotype.
Extrapolation of this data to human samples may help to further
our understanding of the propagation and oncogenesis of
histiocytic cells. Eventually, this will contribute to the development
of effective therapeutic modalities for both species.
Table 5. Ten of the most significant pathways that resulted
from the pathway analyses in DAVID.
Category Term No of genes P-value
KEGG_PATHWAY cfa04142:Lysosome 25 1.62E-05
KEGG_PATHWAY cfa04110:Cell cycle 26 3.44E-05
CHROMOSOME 3 59 4.09E-05
CHROMOSOME 5 102 4.92E-05
CYTOBAND 3 59 5.78E-05
CYTOBAND 5 102 7.71E-05
KEGG_
PATHWAY
cfa03030:DNA
replication
11 4.61E-04
KEGG_
PATHWAY
cfa03050:
Proteasome
12 0.0016
KEGG_
PATHWAY
cfa04115:p53
signaling pathway
13 0.0076
KEGG_
PATHWAY
cfa03430: DNA
mismatch repair
7 0.0076
doi:10.1371/journal.pone.0071094.t005
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